Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Botulinum Toxin Type A · 8 trials · 6 indications
Improvement at follow-up in the experimental groups compared to the placebo group
The amount of sweat measured gravimetrically
Composite endpoint based upon the investigator global assessment and patient assessment of severity of lateral canthal lines
| Arm | Type | Description |
|---|---|---|
| Dose A | EXPERIMENTAL | Botulinum toxin type A |
| Dose B | PLACEBO_COMPARATOR | Placebo comparator |
| Dose C | PLACEBO_COMPARATOR | Placebo comparator |
| Dose D | ACTIVE_COMPARATOR | Dose D: Botulinum Toxin Type A |
| Dose E | PLACEBO_COMPARATOR | Dose E: Placebo |
| Name | Type | Description |
|---|---|---|
| Botulinum toxin type A | BIOLOGICAL | Topical botulinum toxin type A |
| Placebo comparator | BIOLOGICAL | Topical placebo comparator |
| Placebo | DRUG | Placebo, Dose B; dose applied to the lateral canthal lines |
| Active Comparator botulinum toxin | BIOLOGICAL | IM injection |
| Placebo (Dose B) | DRUG | Placebo (Dose B), applied topically at Baseline (Day 0) to the lateral canthal lines |
Inclusion Criteria: * In good general health * Moderate to severe lateral canthal lines when evaluated at rest based on the investigator's global assessment * Moderate to severe lateral canthal lines when evaluated at rest based on the patient assessment of severity Exclusion Criteria: * Any neur...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Krystal Biotech, Inc. | KRYS | 2 | PHASE1 | KB304, KB301 |
Botulinum Toxin Type A is being developed for aesthetic and dermatologic conditions including glabellar frown lines, lateral canthal lines (crow's feet), hyperhidrosis, and skin aging. It is an investigational product studied by Revance Therapeutics in placebo-controlled clinical trials.
Botulinum Toxin Type A targets SNAP25, a hydrolytic enzyme involved in neurotransmitter release. By acting on SNAP25, the drug is designed to affect neuromuscular signaling underlying facial wrinkles and excessive sweating. This mechanism is being evaluated in the dermatologic indications under study.
Botulinum Toxin Type A is being developed by Revance Therapeutics, Inc., which trades under the ticker RVNC. The company is evaluating the product in dermatology indications including glabellar frown lines, lateral canthal lines, hyperhidrosis, and skin aging.
Botulinum Toxin Type A is in Phase 2 development for its dermatologic indications. It is investigational and has not been approved by the FDA. The clinical program includes completed Phase 2 and Phase 3 trials evaluating topical and injectable formulations.
Botulinum Toxin Type A has been studied in completed trials including NCT02580370 for lateral canthal lines, NCT02565732 for primary axillary hyperhidrosis, NCT02303002 for glabellar lines, and NCT01940991 for crow's feet lines. These trials enrolled a total of 779 participants across the United States and Canada.